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acasteras@vhebron.netSummaryIsolated GH deficiency type IA (IGHDIA) is an infrequent cause of severe congenital GHD, often managed by pediatric
endocrinologists, and hence few cases in adulthood have been reported. Herein, we describe the clinical status of a 56-year-
old male with IGHDIA due to a 6.7 kb deletion in GH1 gene that encodes GH, located on chromosome 17. We also describe
phenotypic and biochemical parameters, as well as characterization of anti-GH antibodies after a new attempt made to treat
with GH. The height of the adult patient was 123 cm. He presented with type 2 diabetes mellitus, dyslipidemia, osteoporosis,
and low physical and psychological performance, compatible with GHD symptomatology. Anti-GH antibodies in high titers
and with binding activity (O101 IU/ml) were found 50 years after exposure to exogenous GH, and their levels increased
significantly (O200 U/ml) after a 3-month course of 0.2 mg/day recombinant human GH (rhGH) treatment. Higher doses of
rhGH (1 mg daily) did not overcome the blockade, and no change in undetectable IGF1 levels was observed (!25 ng/ml).
IGHDIA patients need lifelong medical surveillance, focusing mainly on metabolic disturbances, bone status, cardiovascular
disease, and psychological support. Multifactorial conventional therapy focusing on each issue is recommended, as anti-GH
antibodies may inactivate specific treatment with exogenous GH. After consideration of potential adverse effects, rhIGF1
treatment, even theoretically indicated, has not been considered in our patient yet.Learning points:
† Severe isolated GHD may be caused by mutations in GH1 gene, mainly a 6.7 kb deletion.
† Appearance of neutralizing anti-GH antibodies upon recombinant GH treatment is a characteristic feature of
IGHDIA.
† Recombinant human IGF1 treatment has been tested in children with IGHDIA with variable results in height and
secondary adverse effects, but any occurrence in adult patients has not been reported yet.
† Metabolic disturbances (diabetes and hyperlipidemia) and osteoporosis should be monitored and properly treated
to minimize cardiovascular disease and fracture risk.
† Cerebral magnetic resonance imaging should be repeated in adulthood to detect morphological abnormalities that
may have developed with time, as well as pituitary hormones periodically assessed.http://www.edmcasereports.com
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Isolated growth hormone deficiency (IGHD)-associated
short stature is estimated to occur in 1 in 4000–10 000
individuals (1). Although most cases are considered to
be sporadic, a genetic cause is found in about 10–15%
of the patients presenting with marked short stature
(height SDS !K4.5) or having an affected first-degree
relative (up to 40%of the familial cases) (2). Genetic testing
is also recommended in cases exhibiting normal pituitary
morphology on magnetic resonance imaging (MRI). So
far, known genetic factors responsible for IGHD include
defects in GH1 gene or GH-releasing hormone receptor
(GHRHR) gene, more rarely mutations in Bruton’s tyrosine
kinase (BTK) gene, or mild phenotypes of mutations
in HESX1 or SOX3 gene. Besides other pituitary hormone
deficiencies, mutations in PROP1 and POUF1 genes should
also be considered in childhood. Inheritance patterns
and GH disturbance severity have helped traditionally to
classify IGHD into four clinical types (IA, IB, II, and III);
however, themolecular heterogeneitywithin each subtype
makes this classification cumbersome (3) (4) (Table 1).
IGHD type IA (IGHDIA) is characterized by a complete
lack of GH production and exhibits the most severe
phenotype. The syndrome was first described in 1970
in a group of six patients including a Spanish boy who is
the main subject of the case report described herein (5).
Underlying genetics are predominantly GH1 gene
deletions, although nonsense or frameshift mutations
severely disturbing the GH molecule have also been
reported (3). GH1 gene resides on the 17q22–24 chromo-
some within a cluster of 65 kb including five homologous









IA GH1 gene deletions and
nonsense mutations
AR Absent Transitory








III BTK or unknown X-linked Y Yes
AR, autosomal recessive; AD, autosomal dominant; AP, anterior pituitary; PP, p
BTK, Bruton’s tyrosine kinase; Y, low but detectable.
http://www.edmcasereports.comrecombination and crossing over at meiosis. Appearance
of neutralizing anti-GH antibodies (anti-GH Abs) upon
recombinant human GH (rhGH) treatment is a charac-
teristic featureofGHDIA (1) (5). As analternative approach,
recombinant human insulin-like growth factor 1 (rhIGF1)
is being used in children to improve growth parameters;
adult cases have not been reported. Although targeting
growth is not an issue in the surveillance of adults with
GHD, questions remain with respect to the metabolic
disturbances, cardiovascular risk, and lastly longevity.
Case presentation
A 56-year-old male known to have IGHDIA was referred to
our adult endocrinology unit after several years of lapsed
follow-up. He was diagnosed in early childhood with
severe growth retardation (K5.7 S.D. at 2 years of age). His
case was included in pediatric publications as he belonged
to the first group of children having the syndrome when it
was first described (5). He was born from nonconsangui-
neous progenitors and any other family member was not
of short stature. Birth length at 42 weeks of gestation was
already poor (48 cm) and weight was 4080 g. In infancy,
he was of proportionate short stature with certain
phenotypic features such as puppet-face appearance. We
are not aware of hypoglycemic episodes or micropenis
in childhood and he had no problems related to dentition
or puberty. Other pituitary hormonal axis functions
were normal, and initial pituitary image did not reveal
major abnormalities. Genetic study revealed a severe GH1
gene deletion of 6.7 kb in homozygous state. At the age
of 7 years, with a K6 S.D. growth delay, he was given
GH extracted from human pituitaries based on the Raben
method in Zürich Children Hospital (Switzerland) for aGH Pituitary imaging Comments
AP: normal or hypoplastic Often have anti-GH antibodies
after GH replacement
PP: eutopic
AP: normal or hypoplastic
PP: eutopic
AP: normal or hypoplastic Variability in height
PP: eutopic May develop additional pitu-
itary hormone deficiencies
PP: ectopic or normal Agammaglobulinemia
May have mental retardation
osterior pituitary; GHRHR, growth hormone-releasing hormone receptor;
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achieved (K6.2 S.D. at 9 years of age), compatible with the
development of anti-GH Abs. Thus, his final height was
poor, reaching only 123 cm, representing a SDS of K8.46
with respect to the Spanish population. Of interest is
the fact that he leads a normal life, runs a bar, is married,
and has two sons (carriers of 6.7 kb deletions without any
clinical expression). He has been a heavy smoker for the
last 30 years. Now in his fifties, he presents with health
complaints that resembles those of adult GHD. He suffers
from asthenia, osteomuscular pain, and osteoporosis.
Onphysicalexamination (Fig. 1), apart fromsevere short
stature, he was found to weigh 38 kg (BMI 24.71), with waist
circumference being 85.5 cm, hip circumference 83 cm, and
blood pressure 137/71 mmHg. He did not have any sign
of hypogonadism. Genitals were normal with a testicular
size of 20 ml bilaterally. He had a high-pitched voice.Investigation
Blood test revealed normal full blood count as well as
hepatic and renal function. Diabetes was diagnosed basedFigure 1
Fifty-six-year-old male patient, with 6.7 kb deletion in GH1 gene and
height 123 cm.
http://www.edmcasereports.comon a glycohemoglobin level of 6.8% with basal glucose
levels of 128 mg/dl; hypercholesterolemiawas alsopresent:
total cholesterol 247 mg/dl (!220), cLDL 182 mg/dl
(!130), cHDL 32 mg/dl (O40), and triglycerides
166 mg/dl (43–200). Vitamin D deficiency with secondary
parathyroid hormone (PTH) elevation and normal calcemia
was observed: 25OH vitamin D3 6.7 ng/ml (6.6–46.4), PTH
140 pg/ml (7–82), calcium 9 mg/ml, and phosphorus
2.8 mg/dl. The following hormones were present within
thenormal range: thyroid-stimulatinghormone 2.49 mU/l
(0.4–4), free thyroxine 1.05 ng/ml (0.7–1.6), luteinizing
hormone 2.6 U/l (0.8–8), follicle-stimulating hormone
3.6 U/l (0.7–12), total testosterone 484 ng/dl (241–827),
prolactin 3.9 ng/ml (2.1–17.7), cortisol 14 mg/dl (4.3–22.4),
and adrenocorticotropic hormone 12 pg/ml (5–46). The
presence of a clearly suppressed GH axis was remarkable:
GH !0.05 ng/ml (!8 ng/ml), IGF1 !25 ng/ml (69–252),
and IGF-binding protein 3 (IGFBP3) !0.5 mg/l (3.1–7.9).
On cardiovascular evaluation, carotid intima media thick-
ness was found to be within the normal range, 0.6 mm in
both carotids. Atherosclerotic plaques without hemody-
namic repercussion were detected in both carotid bulbs.
Further evaluation of biochemical cardiovascular risk
parameters revealed the following: HOMA-IR 2.2 (insulin
6.5 mU/l (3–25) and glucose 146 mg/dl), HOMA-b 28.3%,
C-reactive protein 0.78 mg/dl (!50), and lipoprotein (a)
2.9 mg/dl (!20). Bone densitometry revealed osteoporosis
(T-scoreK2.7 on lumbar spine andK3.1 on femoral neck).
A score of 18 points was obtained for quality of life assessed
with the QoL–AGHDA questionnaire. New pituitary MRI
done (Fig. 2) showed flattening of the skull base in relation
to platybasia and also a short clivus and a small posterior
cranial fossa, but without herniation of the cerebellar
tonsils below the foramen magnum. There was an
arachnoidocele of the sella turcica enlarging the bony
structure and displacing the pituitary gland toward the
posterior margin.Treatment
As thepatientwas treatedwithaquite impure immunogenic
GH preparation rather than with the current recombinant
GH hormone formulations in childhood, we tried to treat
him again with adult GH dosing, 0.2 mg daily (Genoto-
norm; Pfizer, Inc., New York, NY, USA). After 1 month of
treatment, there was no increase in IGF1 or IGFBP3 levels.
Then, an empirical IGF1 generation test was carried out at
higher doses (0.03 mg/kg per dayZ1 mgGH/day for 5 days),
without achieving any further response (GH33.3 ng/ml and
IGF1 !25 ng/ml). Antibodies against GH were determined3
Figure 2
Cerebral MRI, T1-weighted, sagittal midline. Platybasia, short clivus, and
small posterior cranial fossa. Arachnoidocele of the sella turcica.
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radioprecipitation assay. The antibodies exhibited detect-
able binding activity even basally, i.e. after 50 years of
exposure, and their levels increased tremendously with GH
replacement. Anti-GH Ab levels were initially 101 U/ml
(titer 1:10; reference range !6.03 U/ml) and increased to
O200 U/ml (titer 1:10 000). Owing to the lack of bio-
chemical response or clear clinical benefit, GH therapy was
discontinued. Thus, comorbidities were treated appro-
priately with dietary education, metformin, aspirin, statin,
and calcium plus vitamin D3 supplements. The patient
refused antiresorptive bisphosphonate treatment for the
time being.Outcome and follow-up
After 1 year of follow-up, T2DM was under control (latest
glycohemoglobin 6.6%), lipid levels were within the target
range (cLDL 98), and bone mineral density (BMD)
improved 7.3% in lumbar spine and 1.9% in femoral neck.Discussion
The patient described herein is, to our knowledge, the
oldest adult case of IGHDIA properly described in the
literature. Genetic analysis revealed a 6.7 kb deletion in
GH1 gene that entails an absolute lack of GH. Deletion of
6.7 kb has been reported to be the most common
mutation accounting for the type IA phenotype (78%);
other deletions include 7.6 and 45 kb (3). Less severehttp://www.edmcasereports.commutations in GH1 gene (splice site and missense) exhibit
phenotype IB or II, in which low but detectable GH
concentrations are observed and there is response to GH
replacement. Type IB can also be caused by recessive
GHRHRmutations. Type IA is less frequent than type IB or
type II, accounting for only about 5% of the cases (4).
However, in the work carried out by Wagner et al. (2), the
absolute frequency of GH1 gene deletions in a cohort of
severe short stature (!4.5 S.D.) was 12.5% (19/151),
especially in those of an Asian origin.
Phenotypic appearance of GHDIA includes an already
intrauterine growth retardation (birth length !49 cm,
considerably shorter than nonaffected siblings) and severe
growth delay in childhood, even beyond K4.5 SDS.
Adult height is clearly small, but quite variable in the
few adult cases reported in the literature (130–140 cm), as
some do not produce anti-GH Abs or would not have
received rhIGF1 therapy in childhood (6) (7). Cherubic
facial features derive from midfacial hypoplasia and
forehead prominence. Small posterior fossa and platybasia
described in our patient’s MRI may also reveal bone effects
of lifelong GHD. On the other hand, the pituitary
arachnoidocele found in the MRI is meant to have
developed with time; possibly, it is merely a coincidental
finding, butmore information about adult IGHDIA cases is
lacking. Generally, cases withmutations inGH1 gene have
normal pituitary morphology in contrast to cases with
other causes of congenital GHD such as perinatal insults
that are associated with alterations in the pituitary stalk or
ectopic posterior pituitary lobe. However, some cases
present with anterior hypoplasia, and it is not ruled out
that pituitary image findings may evolve with time.
Oliveira et al. (8) reported anterior pituitary hypoplasia
in patients with inactivating GHRHR mutations, compa-
tible with the lack of GHRH effect on somatotrophs. Our
patient has not developed any other hormonal deficiency
until now. Development of additional pituitary hormone
deficiencies in type II IGHD has been attributed to the
disrupting effects of the aberrant predominance of
17.5 kDa GH isoform on the pituitary gland (9) and thus
this would not be the case in type IA.
The absence of endogenous production of GH in
IGHDIA explains the immune response upon rhGH
administration; however, the appearance of antibodies
may not be a regular finding even among members of the
same family. Moreover, anti-GH Abs may have different
binding affinities, compromising GH coupling to the
receptor. GH1 mutation severity, HLA haplotypes, or
other immune response genes, as well as age at first
antigen contact, could contribute to these differences in4
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disappearing and years thereafter allowing new response
to GH treatment (6). Interestingly, in the present case, the
antibodies had persisted at a low level for many years and
their levels had increased considerably after a new contact
with GH. Efforts to remove anti-GH Abs with plasmapher-
esis or treatment with IgG or cyclophosphamide have
been frustrating and nor has desensitization using small
amounts of exogenous GH prevented their appearance (6).
Physiologically, GH exerts its action on the peripheral
tissues both directly and indirectly with the mediation of
circulating and locally produced IGF1. Severe IGHDIA with
extremely low levels of circulating IGF1 could exhibit
reasonable similarities with Laron’s dwarfism, where a
mutation in GH receptor abolishes the effect of GH on
IGF1 production. Recombinant IGF1 (rhIGF1) represents an
interesting treatment option for children with IGHD1A
developing antibodies or GH insensitivity syndrome (7).
rhIGF1 is not licensed for use in the treatment of adult GHD;
however, in view of the very severe ‘secondary IGF1
deficiency’, it seemsplausible toconsider treatingourpatient
with rhIGF1. Reports of children with type IA is quite recent
and scarce (6) (10) and sometimes disappointing, with them
not achieving a proper catch-up in growth in some cases or
exhibiting secondary adverse effects on lipids and BMI.
It is well known that GHD symptoms in adulthood
include changes in body composition with an increase in
fat body mass in detriment of lean one, decreased bone
mass, unfavorable lipid profile, reduced physical and
cardiac performance, premature atherosclerosis, and
poor quality of life.
BMD in short individuals measured by the standard
two-dimensional methodmay yield false results, oversizing
osteoporosis. Bone mineral apparent density (volumetric
density) allows the calculation of true density, as a bone
mass/volume (11). Thus, we calculated vertebral (L2–L4)
volumetric density as bone mineral content per bone
volume (area of vertebrae (cm2)!height). Volumetric den-
sity was 0.35 g/cm3, compatible with a much better bone
status than obtained by areal density, although a Z-score
for his age and gender group is currently not available.
While GHD or insensitivity might be associated with
hypoglycemia in children, in adults hyperglycemia is
common. The age-related decline in insulin sensitivity in
GH-deficient patients is not well understood yet; however,
we chose to treat the patient with metformin for T2DM, as
it was the most appropriate drug. Insulin resistance may
be the main underlying mechanism for diabetes in our
patient, after central adiposity, older age, and HOMA-IR
value. Nevertheless, recent studies in Laron’s dwarfs andhttp://www.edmcasereports.comin patients with GHRHR gene mutation have reported
normal or reduced HOMA-IR values and elevated adipo-
nectin levels, despite concomitant obesity (12) (13).
Insulin secretion seems to be also compromised in the
latter group after low HOMA-b levels (mean 28.1%), a
value similar to that observed in the present case. It is
hypothesized that significantly reduced IGF1 levels could
compromise b-cell mass. In summary, IGHD would not
protect from the development of diabetes as postulated.
Information on other cardiovascular risk factors in
IGHD is scarce, butnopremature atherosclerosis signshave
been found in untreated type IB patients due to GHRHR
mutations in a Brazilian kindred (14). On the contrary,
the patient described herein had carotid atherosclerotic
plaques, indicating slow progression of atherosclerosis.
This finding may well have a multifactorial origin.
Cancer reports are also anecdotic among Laron’s and
IGHD patients. Reduced IGF1 signaling has been reported
to have a protective effect on aging in some animal
models. However, this cannot be extrapolated to humans,
due to a much more complex endocrine/paracrine net-
work being involved in organ and tissue development as
well as energy homeostasis throughout life. It is fairly
accepted that in the post-developmental stage of life, GH
and IGF1 have numerous beneficial actions in skeletal
muscle and cardiovascular and nervous systems, but a
negative effect on insulin sensitivity and cancer risk. There
is less information on the longevity of GHDIA-affected
patients, except for a report by Besson et al. (15). Life span
was found to be greatly reduced in 11 IGHDIA individuals
compared with nonaffected siblings and normal popu-
lation of the same time and place (Switzerland, late 19th–
early 20th century). Reported survival in GHDIA patients
vs controls was 56 vs 75 years for men and 46 vs 80 years
for women. The causes of death did not vary between
groups: cardiovascular and infections. Of note, there were
no records on cancer or diabetes, although information
sources were not medical. In contrast to acquired
hypopituitarism cases, congenital severe GHD cases have
much lower serum IGF1 levels and have never been
exposed to GH and thus they may not be equivalent in
terms of GH/IGF1 axis disturbances and health prognosis.
In conclusion, establishing the etiologic diagnosis of
GHD in childhood is a major challenge requiring a
combination of clinical, auxological, biochemical, and
pituitary imaging data. Genetic testing is recommended
mainly in case of severe growth delay, familial affected
members, or normal MRI, but exceptions to the rule have
to be considered. This case of IGHDIA shows the
persistence of anti-GH Abs 50 years after the exposure to5
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treatment with recombinant GH preparations. Adult GH
absence and the consequent severe IGF1 deficiency may
underlie the patient’s present metabolic disorders, osteo-
muscular symptoms, and reduced quality of life. However,
at the moment, we choose not to treat the patient with
rhIGF on the basis of risk–benefit.
IGHDIA is an exceptional in vivo model to study
GH/IGF1 actions throughout life. Limitations to extend-
ing conclusions in terms of diabetes, cancer, and longevity
are the few reported cases due to the rarity of the disease
and the multiple in vivo biases such as particularities
within endogamic kindreds or certain life styles.Patient’s perspective
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